Medicare Enrolled
Dr. Frederick Dold, M.D.
Hematology & Oncology · Philadelphia, PA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Dold from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dold?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dold
Dr. Frederick Dold is a hematology & oncology specialist in Philadelphia, PA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Dold performed 78,578 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Dold received a total of $14,965 from 95 pharmaceutical and/or device companies across 731 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dold is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years of NPI registration
▲ Top 8% volume in PA
$14,965 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗78,578
Medicare services
Top 8% in PA for hematology & oncology
Not available
Unique patients (not deduplicated)
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
21,750 | $1 | $4 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
17,740 | $2 | $21 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
11,700 | $0 | $6 |
| Denosumab injection (Prolia/Xgeva) | 11,220 | $18 | $69 |
| Iron infusion (Monoferric) | 5,400 | $16 | $73 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
3,585 | $6 | $30 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,520 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 960 | $1 | $122 |
| Injection, granisetron hydrochloride, 100 mcg | 830 | $0 | $25 |
| Pegfilgrastim-apgf injection An injection of pegfilgrastim-apgf, a biosimilar medication. The dose specified is 0.5 mg. |
576 | $93 | $879 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
546 | $102 | $224 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
458 | $13 | $105 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
386 | $12 | $93 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
363 | $110 | $686 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
220 | $69 | $148 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
211 | $24 | $152 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
167 | $61 | $205 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
131 | $1 | $7 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
114 | $1 | $9 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
104 | $53 | $304 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
87 | $24 | $156 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
86 | $143 | $301 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
80 | $54 | $334 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
64 | $63 | $157 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
56 | $131 | $345 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
50 | $107 | $297 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
48 | $47 | $281 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
42 | $11 | $73 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
30 | $2 | $19 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
24 | $27 | $249 |
| New patient office visit, complex (60-74 min) | 17 | $168 | $432 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
13 | $142 | $412 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
35.6% high complexity
62.9% medium
1.5% routine
Industry Payment Transparency
Open Payments through 2024 ↗$14,965
Total received (2018-2024)
Avg $2,138/year across 7 years
Top 18% in PA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
95
Companies
731
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,745
2023
$2,879
2022
$2,240
2021
$1,458
2020
$934
2019
$2,879
2018
$1,830
Payments by company (2024)
Janssen Biotech, Inc.
$234
GENZYME CORPORATION
$207
ABBVIE INC.
$196
Novartis Pharmaceuticals Corporation
$170
AstraZeneca Pharmaceuticals LP
$158
Incyte Corporation
$117
Merck Sharp & Dohme LLC
$116
Eisai Inc.
$86
E.R. Squibb & Sons, L.L.C.
$75
Bayer Healthcare Pharmaceuticals Inc.
$73
Genentech USA, Inc.
$70
SOBI, INC
$70
Lilly USA, LLC
$70
Karyopharm Therapeutics Inc.
$64
Gilead Sciences, Inc.
$64
Celgene Corporation
$62
EAGLE PHARMACEUTICALS, INC.
$61
PFIZER INC.
$60
Regeneron Healthcare Solutions, Inc.
$57
Genmab U.S., Inc.
$51
Alnylam Pharmaceuticals Inc.
$50
Astellas Pharma US Inc
$50
Sumitomo Pharma America, Inc.
$49
Daiichi Sankyo Inc.
$45
PharmaEssentia USA Corporation
$43
PUMA BIOTECHNOLOGY, INC.
$40
Stemline Therapeutics Inc.
$37
GlaxoSmithKline, LLC.
$34
Takeda Pharmaceuticals U.S.A., Inc.
$34
Blueprint Medicines Corporation
$28
Alexion Pharmaceuticals, Inc.
$24
Ipsen Biopharmaceuticals, Inc
$24
Tempus AI, Inc
$23
Mirati Therapeutics, Inc.
$23
Pharmacosmos Therapeutics Inc.
$23
Myriad Genetic Laboratories, Inc.
$21
JAZZ PHARMACEUTICALS INC.
$20
RECORDATI_RARE_DISEASES_INC.
$19
ADC Therapeutics America, Inc.
$17
EMD Serono, Inc.
$17
TerSera Therapeutics LLC
$16
Acrotech Biopharma Inc.
$16
Rigel Pharmaceuticals, Inc.
$16
Deciphera Pharmaceuticals Inc.
$14
Top 3 companies account for 23.2% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,065
Janssen Biotech, Inc.
$745
Genentech USA, Inc.
$700
AstraZeneca Pharmaceuticals LP
$662
E.R. Squibb & Sons, L.L.C.
$642
GENZYME CORPORATION
$553
Celgene Corporation
$547
Lilly USA, LLC
$476
Amgen Inc.
$463
PFIZER INC.
$387
Merck Sharp & Dohme Corporation
$363
Eisai Inc.
$359
Astellas Pharma US Inc
$356
Incyte Corporation
$353
Paratek Pharmaceuticals, Inc.
$332
Daiichi Sankyo Inc.
$331
Takeda Pharmaceuticals U.S.A., Inc.
$306
TESARO, Inc.
$288
Seagen Inc.
$269
Bayer HealthCare Pharmaceuticals Inc.
$267
Merck Sharp & Dohme LLC
$257
Boehringer Ingelheim Pharmaceuticals, Inc.
$242
Pharmacyclics LLC, An AbbVie Company
$237
ABBVIE INC.
$228
EISAI INC.
$207
EAGLE PHARMACEUTICALS, INC.
$204
Foundation Medicine, Inc.
$158
Gilead Sciences, Inc.
$146
Bayer Healthcare Pharmaceuticals Inc.
$144
Puma Biotechnology, Inc.
$142
EMD Serono, Inc.
$131
Ipsen Biopharmaceuticals, Inc
$123
Alexion Pharmaceuticals, Inc.
$122
MorphoSys, US Inc.
$115
GlaxoSmithKline, LLC.
$112
Karyopharm Therapeutics Inc.
$111
Regeneron Healthcare Solutions, Inc.
$110
AbbVie Inc.
$107
Exelixis Inc.
$98
Genmab U.S., Inc.
$93
Kite Pharma, Inc.
$93
Blueprint Medicines Corporation
$92
Stemline Therapeutics Inc.
$88
Dendreon Pharmaceuticals LLC
$81
G1 Therapeutics, Inc.
$80
Sumitomo Pharma America, Inc.
$79
BeiGene USA, Inc.
$78
Pharmacosmos Therapeutics Inc.
$78
Myovant Sciences Inc.
$78
PUMA BIOTECHNOLOGY, INC.
$76
Myriad Genetic Laboratories, Inc.
$73
Taiho Oncology, Inc.
$70
SOBI, INC
$70
Mirati Therapeutics, Inc.
$68
Seattle Genetics, Inc.
$66
Kyowa Kirin, Inc.
$60
Rigel Pharmaceuticals, Inc.
$60
Helsinn Therapeutics (U.S.), Inc.
$56
Emmaus Medical, Inc.
$55
ADC Therapeutics America, Inc.
$54
Deciphera Pharmaceuticals Inc.
$53
Alnylam Pharmaceuticals Inc.
$50
Novocure Inc.
$48
AbbVie, Inc.
$46
PharmaEssentia USA Corporation
$43
TerSera Therapeutics LLC
$42
ARRAY BIOPHARMA INC
$41
Pharmacyclics LLC, an AbbVie Company
$40
Acrotech Biopharma LLC
$40
Janssen Pharmaceuticals, Inc
$34
Apellis Pharmaceuticals, Inc.
$33
Acrotech Biopharma Inc.
$33
ImmunoGen, Inc.
$29
Clovis Oncology, Inc.
$29
Clinigen Inc
$28
SERVIER PHARMACEUTICALS LLC
$28
Aadi Bioscience, Inc.
$25
Jazz Pharmaceuticals Inc.
$25
Tempus AI, Inc
$23
Spectrum Pharmaceuticals Inc.
$22
Sun Pharmaceutical Industries Inc.
$21
EUSA Pharma (US) LLC
$21
JAZZ PHARMACEUTICALS INC.
$20
Dova Pharmaceuticals
$19
RECORDATI_RARE_DISEASES_INC.
$19
Organon LLC
$18
Heron Therapeutics, Inc.
$18
Adaptive Biotechnologies Corporation
$18
Global Blood Therapeutics, Inc.
$16
Advanced Accelerator Applications
$16
Acceleron Pharma, Inc.
$14
TOLMAR Pharmaceuticals, Inc.
$13
Teva Pharmaceuticals USA, Inc.
$11
Mylan Pharmaceuticals Inc.
$11
AMAG Pharmaceuticals, Inc.
$11
Top 3 companies account for 16.8% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · AKYNZEO · ALIMTA · ALUNBRIG · AMVUTTRA · AUGTYRO · AYVAKIT · Abraxane · Alecensa · Aliqopa · Avastin · BAVENCIO · BELEODAQ · BENDEKA · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · Bavencio · Blincyto · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CINVANTI · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · ERBITUX · ERLEADA · EXKIVITY · Elahere · Empaveli · Endari · Enhertu · Epkinly · FASLODEX · FERAHEME · FOLOTYN · FOUNDATIONONE · Fabhalta · Fulphila · Fyarro · GAUCHER-DISEASE · GAZYVA · GILOTRIF · HYQVIA · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · Imbruvica · Inrebic · JAKAFI · JEVTANA · KEYTRUDA · KISQALI · KRAZATI · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lonsurf · Lutathera · MEKINIST · MONJUVI · MONOFERRIC · MYRISK · Monoferric · NERLYNX · NINLARO · NUZYRA · Nerlynx · Nplate · Nubeqa · OJJAARA · ONTRUZANT · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Oncology · Onivyde · Orserdu · PADCEV · PEMAZYRE · PEMFEXY · PIQRAY · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · Perjeta · Polivy · Pomalyst · Poteligeo · Proleukin · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · Reblozyl · Revlimid · Rezlidhia · Rozlytrek · Rubraca · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SOLIRIS · SOMATULINE DEPOT · SUTENT · SYLVANT · Somatuline Depot · Stivarga · Sylvant · TABRECTA · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TIVDAK · TRUSELTIQ · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tibsovo · Tivdak · Trodelvy · ULTOMIRIS · Ultomiris · VARUBI · VENCLEXTA · VERZENIO · VONJO · VPRIV · Venclexta · Vitrakvi · WELIREG · XALKORI · XARELTO · XPOVIO · XTANDI · Xofigo · Xospata · Xtandi · YONSA · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX · ZYTIGA · Zoladex · clonoSEQ · myRisk
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
274
County median income
$60,698
Nearest hospital to ZIP centroid (approximate)
JEFFERSON HEALTH- NORTHEAST
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Dold is a mixed practice specialist, with above-average Medicare volume (top 8% in PA), with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Dold experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Dold performed 21,750 iron infusion (injectafer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Dold receive payments from pharmaceutical companies?
Yes. Dr. Dold received a total of $14,965 from 95 companies across 731 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dold's costs compare to other hematology & oncology specialists in Philadelphia?
Dr. Dold's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dold) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Philadelphia
Browse hematology & oncology specialists in Philadelphia ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in PA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in PA
Which PA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc.
By company
Genentech USA, Inc. Payments to Doctors
See all physicians who received payments from Genentech USA, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology